The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease
Open accessAbstract
Background— Interaction of CD40L with its receptor CD40 is critically involved in inflammatory cell activation in atherogenesis. In addition, serum levels of soluble CD40L are elevated in acute coronary syndromes and have been associated with increased cardiovascular risk in healthy subjects, thus making sCD40L an intriguing target to modulate the inflammatory response in the vasculature. PPARγ-activating thiazolidinediones, novel insulin-sensitizing antidiabetic agents, have recently been shown to exhibit antiinflammatory effects in the vessel wall. To examine whether thiazolidinedione treatment might modulate serum levels of sCD40L in high-risk patients, we performed a randomized, placebo-controlled, single-blinded trial to assess the effect of rosiglitazone on sCD40L levels in patients with type 2 diabetes and coronary artery disease (CAD). Methods and Results— Thirty-nine patients with diabetes and angiographically proven CAD were randomized to receive rosiglitazone (4 mg BID) or placebo for 12 weeks. Baseline parameters did not significantly differ between groups. Rosiglitazone treatment, but not placebo, significantly reduced sCD40L serum levels within the first 2 weeks by 8.1% (17.1 to −32.7) (median percentage [interquartile range]; P <0.05 compared with baseline), further decreasing it by 18.4% (−5.0 to −33.1) after 6 weeks ( P <0.05 compared with baseline), and by 27.5% (8.2 to −70.5) after 12 weeks ( P <0.05 compared with baseline and with 2 weeks of treatment). Conclusion— Treatment with the PPARγ-activating thiazolidinedione rosiglitazone reduces sCD40L serum levels in patients with type 2 diabetes and CAD. These data support an antiinflammatory and potentially antiatherogenic effect of thiazolidinediones.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Cited by
Adiponectin as an anti-inflammatory factor
Ouchi, N., & Walsh, K. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.01.026 · Cited by 872
Marx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501
Self-citationPharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
Peroxisome proliferator-activated receptors and inflammation
Moraes, L. A., Piqueras, L., & Bishop-Bailey, D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.007 · Cited by 376
Inflammatory Markers and the Metabolic Syndrome
Koh, K. K., Han, S. H., & Quon, M. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.082 · Cited by 368
Metadata
- Authors
- Marx, N., Imhof, A., Froehlich, J., Siam, L., Ittner, J., Wierse, G., Schmidt, A., Maerz, W., Hombach, V., & Koenig, W.
- Venue
- Circulation
- Published
- 2003-04-22
- Volume
- 107
- Issue
- 15
- Pages
- 1954-1957
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2008674682
- Cited by
- 215
- References
- 1
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease. https://app.cochat.ai/papers/10.1161/01.cir.0000069272.06194.91
- The paper
- Marx, N., Imhof, A., Froehlich, J., Siam, L., Ittner, J., Wierse, G., Schmidt, A., Maerz, W., Hombach, V., & Koenig, W. (2003). Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease. Circulation. https://doi.org/10.1161/01.cir.0000069272.06194.91
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.